Innova Captab IPO

Innova Captab Limited

₹14,058 /33 sharesMinimum Investment

Innova Captab IPO Listing Details

Listed OnIssue Price
BSE & NSE₹448.00

Innova Captab IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
21 Dec ‘23 - 26 Dec ‘23₹14,05833₹426 - ₹448
Issue SizeIPO Doc
570.00Cr
RHP PDF

Subscription Status As on 26 Dec '23, 5:05 PM

  • Qualified Institutional Buyers
    116.73x
  • Non-Institutional Investor
    64.94x
  • Retail Individual Investor
    17.15x
  • Total
    55.26x

About Innova Captab

Innova Captab is a pharma company involved in research, development, manufacturing, drug distribution, marketing, and exports. The company started its journey by offering contract development and manufacturing organization (CDMO) services to various Indian pharmaceutical companies, alongside its domestic and international branded generics businesses. It has 2 manufacturing facilities in Baddi, Himachal Pradesh, and is planning for a new facility in Jammu. Innova Captab has expanded its portfolio to over 600 diverse generic products, marketed under its own brands in India through a network of 5,000 distributors and 150,000 retail pharmacies. The company also brands generic products to numerous countries. Offering a range of products from oral solids to injectables and using new technologies like nano technology, Innova Captab caters to both acute and chronic therapeutic areas.;
Parent Organisation
Innova Captab Limited
Founded
2005
Managing Director
Mr. Vinay Kumar Lohariwala

Strengths & Risks

  • The company has a diverse range of over 600 products across various therapeutic areas, including complex formulations like modified and sustained-release forms and tablets in capsules. This wide-ranging portfolio enables them to cater to a broad spectrum of healthcare needs.
  • Innova Captab emphasizes robust in-house R&D, which aids in attracting CDMO customers and growing its branded generic portfolio. They have a dedicated R&D facility, recognized by the Department of Scientific and Industrial Research, India.
  • The company operates state-of-the-art manufacturing facilities which are certified for Good Manufacturing Practices.
  • Innova Captab has expanded its international presence, exporting branded generics to numerous countries.
  • One of the fastest growing CDMOs in the Indian pharmaceutical formulations market, as per a CRISIL report.
  • In the financial year 2023, the company had 182 CDMO customers including Cipla, Glenmark Pharma, Wockhardt, Corona Remedies, Emcure Pharma, Lupin and Mankind Pharma.
  • According to CRISIL Research, the company ranked 3rd among its peers in terms of finished tablet and capsule manufacturing capacity in India.
  • Innova Captab's restated consolidated financial information lacks comparability over different periods. The pro forma condensed consolidated financial information, not prepared in accordance with generally accepted accounting principles, may change and fail to provide an accurate representation of the company's operational or financial status.
  • The recent acquisition of Sharon presents uncertainties for Innova Captab. They are yet to ascertain if the expected benefits of this acquisition will materialize, posing a potential risk to their business stability and financial outcomes.
  • Innova Captab's reliance on a few contract development and manufacturing organization customers brings risk. A reduction in these customers or inability to maintain these relationships could significantly impact their business operations and financial health.
  • The company has incurred substantial capital expenditure in recent years and requires significant financing for ongoing operations and planned expenditures. Any challenges in securing finance could hinder their growth and profitability.
  • Innova Captab’s dependence on China, China SEZ, and Hong Kong for raw materials exposes them to risks associated with the political, economic, and social conditions in these regions.
  • The requirement to transfer, obtain, renew, or maintain statutory and regulatory permits, licenses, and approvals for Sharon’s business poses a risk. Delays or failures in this compliance could adversely affect Innova Captab’s operations and financial condition.
  • Innova Captab's history of related party transactions, which may continue, raises concerns about potential conflicts of interest. A significant portion of their revenue comes from these transactions, potentially impacting shareholder interests.
  • Dependence on third parties for clinical trials introduces risk. Any failure to meet regulatory standards by these parties could delay regulatory approvals, adversely affecting the company’s business and financial status.
  • The company’s expansion plans, including the construction of a new facility in Jammu, are subject to risks like unexpected delays and cost overruns. These could impact their growth strategy and financial stability.
  • Innova Captab must navigate diverse international regulations for product exports, adding complexity and risk. Failure to comply with these regulations could have adverse effects on their business and financial results.
  • A significant portion of Innova Captab's sales are on open credit, exposing them to the risk of non-payment. An increase in bad debts or defaults by customers could impact their profitability and cash flows.
  • The location of their manufacturing and R&D facilities in Himachal Pradesh exposes Innova Captab to specific geographic risks like labor unrest and natural disasters, potentially disrupting operations.

Financials

*All values are in Rs. Cr
No Graph Data To Display

Application details

Apply asPrice bandApply upto
Regular426 - 448₹2 Lakh
High Networth Individual426 - 448₹2 - 5 Lakh
For Innova Captab IPO, eligible investors can apply as Regular.
ⓒ 2016-2024 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 4.7.4
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK MAHINDRA |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  BANDHAN |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  IDBI |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ |  BAJAJ

ABOUT GROWW